Schedule 13G ownership disclosure

Amylyx Pharmaceuticals Inc

Common Stock, par value $0.0001 per share · CUSIP: 03237H101

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Panacea Venture Healthcare Fund II, L.P.

    Shares: 2,200,000 · Class: 2.6%

  • Panacea Venture Healthcare Fund II GP Company, Ltd.

    Shares: 2,200,000 · Class: 2.6%

  • Panacea Innovation Limited

    Shares: 2,200,000 · Class: 2.6%

  • James Huang

    Shares: 2,200,000 · Class: 2.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-021288
Form type
SCHEDULE 13G/A
Filer
Amylyx Pharmaceuticals, Inc.
CIK
CIK 1658551
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub